'Immune Fog' May Reveal Lung Cancer Risk Years Before Tumors Form

A "rising fog" inside the immune system may be one of the earliest detectable signs that lung cancer is on its way — and, according to researchers at University College London (UCL), it may also be a signal that can be cleared. Their new study, published in Nature, describes a gradual shift in immune activity that can appear months or years before a tumor takes shape, potentially opening a window to intercept the disease while it is still in its precancerous stages.

At the center of the finding are regulatory T cells, or Tregs — a specialized class of immune cells whose normal job is to hold other immune cells back, pausing their activity so that the body does not attack itself. In people who went on to develop lung cancer, the UCL team found that these cells built up over time. The result, the researchers suggest, is an immune environment that is effectively muffled, allowing abnormal cells to slip through the body's surveillance system and develop into cancer unchallenged.

Why Early Detection Matters So Much

The stakes for catching lung cancer early are unusually high. According to the figures cited in the research, there are around 32,800 lung cancer deaths in the United Kingdom every year, and only about one in ten people diagnosed with the disease — 11.1% — are predicted to survive for ten years or more. Those outcomes are shaped largely by timing: by the time lung cancer produces noticeable symptoms, it is often advanced and much harder to treat.

That reality has pushed cancer researchers toward the idea of interception rather than treatment — finding high-risk individuals before tumors form and intervening while the disease is still a precursor. The UCL work fits squarely into that effort, arguing that the immune system itself may broadcast a warning long before imaging or symptoms reveal anything.

How the Researchers Tracked the Signal

To follow the phenomenon, the team analyzed blood and tissue samples collected from participants in long-running lung cancer surveillance and screening studies. These cohorts allowed the scientists to look backward, comparing immune activity in people who later developed cancer with those who did not.

The analysis relied on matched single-cell techniques — single-cell RNA sequencing and single-cell T-cell receptor sequencing of CD4+ T cells taken from paired peripheral blood and tissue samples — which gave the team a fine-grained view of which immune cells were present and how they were behaving. Working with the Medical Research Council, the study was reviewed under standard scientific editorial scrutiny and published in the peer-reviewed journal Nature.

What the cell data showed

What emerged was a pattern rather than a single event. Regulatory T cells did not spike suddenly; they accumulated gradually, in the months and years leading up to a diagnosis. The study's lead authors, associate professor James Reading and professor Sam Janes, describe this as a kind of fog settling over the immune system's ability to spot and attack emerging tumors.

Reading has said the finding came together when several members of his team independently reported seeing the same unusual regulatory T cell activity — a convergence that persuaded the group they were looking at something real rather than noise.

Testing the Idea — and Trying to Reverse It

Identifying a signal is only half the story. The UCL team went further, using prototype blood tests to follow the rising immune fog in samples, and then attempting to reverse it using drugs. That reversal is the element the researchers consider most significant: if the fog can be cleared, it may be possible to restore the immune system's ability to intercept precancerous lesions before they become tumors.

To understand what tips a precancer — often described as a lesion — into a full-fledged tumor, the team also examined comparable processes in mice. Animal models let the scientists probe mechanisms that cannot be tested directly in humans, complementing the human cohort data and helping explain why some lesions progress while others do not.

In the Researchers' Own Words

Reading framed the work in terms of prevention. He noted that new ways to prevent lung cancer in people at high risk of developing the disease are urgently needed. What struck the team, he said, was that the regulatory T cell activity was not merely a warning sign that cancer might be developing — it also appeared possible to target that immune fog and intervene, potentially stopping tumors from forming.

That dual role is what makes the discovery attractive as a preventive strategy. A biomarker that only predicts risk is useful for screening; a biomarker that can also be acted upon is a potential treatment pathway.

Key Takeaways From the Study

• Regulatory T cells gradually accumulate months or years before lung cancer is diagnosed.
• These cells normally restrain other immune cells, which may let precancerous lesions escape immune detection.
• Researchers followed the signal using prototype blood tests and then reversed it using drugs.
• Human blood and tissue samples from long-running screening studies were paired with mouse experiments.
• The long-term goal is interception — preventing tumors from forming in high-risk people rather than treating them once symptoms appear.

What Still Needs to Be Shown

The work rests on prototype blood tests rather than routine clinical tools, and the study's ambitions are preventive rather than immediately clinical. Translating a detectable immune signal into a widely usable screening test means validating it across larger populations and confirming that acting on the signal genuinely changes outcomes. Likewise, demonstrating that a drug can reverse the fog in humans — safely and durably — is a separate and substantial step from showing the effect in samples and animal models.

Still, the direction of travel is notable. Much of cancer research focuses on treating established disease; this study points toward an earlier frontier, where the immune system's own quiet drift becomes the thing clinicians watch — and perhaps correct. If the immune fog can be reliably detected and lifted, the years before a lung tumor forms may become the moment when the disease is stopped rather than merely found.

This article is based on reporting by Medical Xpress. Read the original article.